Aequus Pharmaceuticals (CVE:AQS) CEO Doug Janzen joined Steve Darling in the Vancouver Proactive studio to give details about his company. Those detail include drugs already at market and others in the pipeline.
Janzen also shared information on one of those drugs, Aequus 1303 which is being developed to help pregnant women with nausea. Janzen also talked about their revenue streams and future outlook for the company.
Price: 0.215 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...
